期刊文献+

贝特类和他汀类降脂药物联合使用对社区糖尿病患者视网膜病变的防治及护理 被引量:6

下载PDF
导出
摘要 目的:研究分析贝特类和他汀类降脂药物联合应用对社区内糖尿病患者视网膜病变的防治效果及护理方法。方法:将2013年12月至2014年11月社区内54例糖尿病患者视网膜病变患者为研究对象,根据自愿原则将患者分组并采用不同方式进行防治护理,并对评价指标进行统计对比分析。结果:采用特类和他汀类降脂药物联合使用及采用针对性护理的观察组的三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FBG)指标值显著优于采用他汀类降脂药物进行治疗并采用常规方式护理的对照组,差异具有统计学意义(P<0.05);两组患者治疗后的视网膜病变症状明显好转,较治疗前比较,差异具有统计学意义(P<0.05),观察组比对照组好转明显,差异具有统计学意义(P<0.05)。结论:采用贝特类联合他汀类降脂药物并采用针对性护理可显著改善患者的血脂指标值,并使患者的病变症状得到有效控制和改善,具有较高的治疗用药价值。
作者 林仙
出处 《深圳中西医结合杂志》 2017年第10期174-175,共2页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献2

二级参考文献19

  • 1[10]Murdock D K, Murdock A K, Murkock R W, et al . Longterm safety and efficacy of combination gemfibrozil and HMGCoA reductase inhibitors for the treatment of mixed lipid disorders[J]. Am Heart J, 1999,138(1 Pt 1):151-155.
  • 2[11]Iliadis E A, Rosenson R S. Long-term safety of pravastatingemfibrozil therapy in mixed hyperlipidemia[J]. Clin Cardiol,1999,22 (1): 25-28.
  • 3[12]Pauciullo P, Borgnino C, Panletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidemia ( FACT study ) [ J ].Atherosclerosis, 2001,150(2) :429-436.
  • 4[1]Neaton J D, Wentworth D. Serum cholesterol, blood presure,cigarette smoking, and death from coronary heart disease.Overall findings and differences by age for 316 099 white men.Multiple Risk Factor Intervention Trial Research Group[J].Arch Intern Med, 1992,152 (1): 56-64.
  • 5[2]Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in4 444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study[J]. Lancet, 1994,344(8934): 1383-1389.
  • 6[4]The Long-Term Intervention with Pravastatin in Ischemic Disease(LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels[J].N Engl J Med, 1998,339(19) :1349-1357.
  • 7[5]Fric M H, Elo O, Haapa K, et al . Helsinki Heart Study:primary-prevertion trial with gemfibrzil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease[J]. N Engl J Med, 1987,317(20) :1237-1245.
  • 8[6]Rubins H B, Robins S J, Collins D, et al . Gemfibrozil for the secondary prevention or coronary heart disease in men with olw levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Trial Study Group[J].N Engl J Med, 1999,341(6) :410-418.
  • 9[7]Canner P L, Berge K G, Wenger N K, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin[J]. J Am Coll Cardiol, 1986,8(6): 1245-1255.
  • 10[8]Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel Ⅲ)[J].JAMA, 2001,285(19): 2486-2497.

共引文献8

同被引文献39

引证文献6

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部